Hancock S L, Cox R S, McDougall I R
Department of Radiation Oncology, Stanford University School of Medicine, Calif.
N Engl J Med. 1991 Aug 29;325(9):599-605. doi: 10.1056/NEJM199108293250902.
Thyroid disease, especially hypothyroidism, is common in patients with Hodgkin's disease who have been treated with irradiation. We reviewed the records of 1787 patients (740 women and 1047 men) with Hodgkin's disease who were treated with radiation therapy alone (810 patients), radiation and chemotherapy (920 patients), or chemotherapy alone (57 patients) at Stanford University between 1961 and 1989. Among these patients, 1533 were alive at the last follow-up, and 254 had died of causes other than Hodgkin's disease. (Four other patients were excluded from the analysis because they had undergone thyroidectomy before treatment for Hodgkin's disease. The thyroid was irradiated in 1677 patients. Follow-up averaged 9.9 years.
A total of 573 patients had clinical or biochemical evidence of thyroid disease. Among the 1677 patients whose thyroid was irradiated, the actuarial risk of thyroid disease 20 years after treatment was 52 percent, and it was 67 percent at 26 years. Hypothyroidism was found in 513 patients. A total of 486 patients received thyroxine therapy for elevated serum thyrotropin concentrations and either low free thyroxine (208 patients) or normal free thyroxine values (278 patients); 27 had transient elevations of the serum thyrotropin level that were not treated. Graves' hyperthyroidism developed in 30 patients (2 of whom had not undergone thyroid irradiation), and ophthalmopathy developed in 17 of these patients. Ophthalmopathy developed in four other patients with Graves' disease during a period of hypothyroidism (n = 3) or euthyroidism (n = 1). The risk of Graves' disease was 7.2 to 20.4 times that for normal subjects. Silent thyroiditis with thyrotoxicosis developed in six patients. Forty-four patients were found to have single or multiple thyroid nodules, 26 of whom underwent thyroidectomy. Six of the 44 had papillary or follicular cancers. Among the patients who did not undergo operation, 12 had small functioning nodules, 4 had cysts, and 2 had multinodular goiters. The actuarial risk of thyroid cancer was 1.7 percent. The risk of thyroid cancer was 15.6 times the expected risk.
High risks of thyroid disease persist more than 25 years after patients have received radiation therapy for Hodgkin's disease, reinforcing the need for continued clinical and biochemical evaluation. Prolonged follow-up confirms an elevated risk of thyroid cancer and Graves' disease as well as hypothyroidism in these patients.
甲状腺疾病,尤其是甲状腺功能减退症,在接受过放疗的霍奇金病患者中很常见。我们回顾了1961年至1989年间在斯坦福大学接受治疗的1787例霍奇金病患者(740例女性和1047例男性)的记录,这些患者分别接受单纯放疗(810例)、放疗与化疗联合(920例)或单纯化疗(57例)。在这些患者中,1533例在最后一次随访时存活,254例死于霍奇金病以外的原因。(另有4例患者因在霍奇金病治疗前已接受甲状腺切除术而被排除在分析之外。1677例患者的甲状腺接受了照射。随访平均9.9年。
共有573例患者有甲状腺疾病的临床或生化证据。在1677例甲状腺接受照射的患者中,治疗后20年甲状腺疾病的精算风险为52%,26年时为67%。513例患者被诊断为甲状腺功能减退症。共有486例患者因血清促甲状腺素浓度升高且游离甲状腺素水平低(208例)或游离甲状腺素值正常(278例)而接受甲状腺素治疗;27例患者血清促甲状腺素水平有短暂升高但未接受治疗。30例患者发生格雷夫斯甲状腺功能亢进症(其中2例未接受甲状腺照射),其中17例出现眼病。另外4例格雷夫斯病患者在甲状腺功能减退期(n = 3)或甲状腺功能正常期(n = 1)出现眼病。格雷夫斯病的风险是正常受试者的7.2至20.4倍。6例患者发生无痛性甲状腺炎伴甲状腺毒症。44例患者发现有单个或多个甲状腺结节,其中26例接受了甲状腺切除术。44例中有6例患有乳头状或滤泡状癌。在未接受手术的患者中,12例有小的功能性结节,4例有囊肿,2例有多结节性甲状腺肿。甲状腺癌的精算风险为1.7%。甲状腺癌的风险是预期风险的15.6倍。
霍奇金病患者接受放疗后25年以上,甲状腺疾病的高风险仍然存在,这进一步证明了持续进行临床和生化评估的必要性。长期随访证实这些患者患甲状腺癌、格雷夫斯病以及甲状腺功能减退症的风险增加。